Cristina Popescu
Cristina Popescu has a total of 422 co-authors. Here are the top co-authors by number of shared publications:
Mihaela Rădulescu
7 shared publicationsVictoria Aramă
7 shared publicationsAlina Lobodan
National Institute for Infectious Diseases "Prof. Dr. Matei Balş", Bucharest, Romania
6 shared publicationsVioleta Molagic
National Institute for Infectious Diseases "Prof. Dr. Matei Balş", Bucharest, Romania
6 shared publications- Cătălin Tilişcan
Department II, Pathophysiology and Immunology, Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
4 shared publications Daniela Munteanu
National Institute for Infectious Diseases "Prof. Dr. Matei Balş", Bucharest, Romania
4 shared publications
Latest Publications
- 18 January 2019
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 35 (3) , 459-464
Hepatitis B and C Virus Reactivation Patterns in a Romanian Cohort of Patients with Chronic Lymphoproliferative Disorders
Hepatitis B and C virus (HBV and HCV) reactivations have become more common following the intensive use of biological therapies for the treatment of chronic lymphoproliferative disorders (CLD). We evaluate risk factors for virus reactivation and exitus in patients diagnosed with CLD and HBV or HCV infection, undergoing rituximab-chemotherapy (R-chemo). A prospective, observational study in two tertiary-care Romanian hospitals, between December 2007 and May 2010, of patients diagnosed with CLD undergoing R-chemo. HBV and HCV serological markers, viral load, fibrosis and necroinflammation were assessed at baseline and every 3–6 months. We screened 502 patients diagnosed with CLDs (77.2% non-Hodgkin lymphomas) and enrolled 57 patients with HBV and/or HCV infection with a mean age of 61.35 ± 11.1 years. The replicative virus was HBV in 23 patients (40.3%), HCV in 33 patients (57.9%). HCV reactivation rate (15.6%) was lower than for HBV (45.5%) (p = 0.02). In univariate analysis, viral reactivation was associated with aggressive CLD (p = 0.01), HBV (p = 0.01) and lymphopenia (p = 0.02). Death was associated with aggressive CLD (p = 0.01), viral reactivation (p = 0.001) and high baseline viremia (p = 0.05). In multivariate analysis, viral reactivation was associated with lymphopenia (OR 0.05, 95% CI 0.003–0.85, p = 0.03). Risk of death was 10 times higher for patients with viral reactivation (95% CI 1.54–65.5, p = 0.01). A quarter of the infected patients were diagnosed with viral reactivation. While hepatitis C was more prevalent than hepatitis B in patients with CLD, viral reactivation was found 3 times more frequently in patients with hepatitis B than C.
- 18 January 2019
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 35 (3) , 459-464
Hepatitis B and C Virus Reactivation Patterns in a Romanian Cohort of Patients with Chronic Lymphoproliferative Disorders
Hepatitis B and C virus (HBV and HCV) reactivations have become more common following the intensive use of biological therapies for the treatment of chronic lymphoproliferative disorders (CLD). We evaluate risk factors for virus reactivation and exitus in patients diagnosed with CLD and HBV or HCV infection, undergoing rituximab-chemotherapy (R-chemo). A prospective, observational study in two tertiary-care Romanian hospitals, between December 2007 and May 2010, of patients diagnosed with CLD undergoing R-chemo. HBV and HCV serological markers, viral load, fibrosis and necroinflammation were assessed at baseline and every 3–6 months. We screened 502 patients diagnosed with CLDs (77.2% non-Hodgkin lymphomas) and enrolled 57 patients with HBV and/or HCV infection with a mean age of 61.35 ± 11.1 years. The replicative virus was HBV in 23 patients (40.3%), HCV in 33 patients (57.9%). HCV reactivation rate (15.6%) was lower than for HBV (45.5%) (p = 0.02). In univariate analysis, viral reactivation was associated with aggressive CLD (p = 0.01), HBV (p = 0.01) and lymphopenia (p = 0.02). Death was associated with aggressive CLD (p = 0.01), viral reactivation (p = 0.001) and high baseline viremia (p = 0.05). In multivariate analysis, viral reactivation was associated with lymphopenia (OR 0.05, 95% CI 0.003–0.85, p = 0.03). Risk of death was 10 times higher for patients with viral reactivation (95% CI 1.54–65.5, p = 0.01). A quarter of the infected patients were diagnosed with viral reactivation. While hepatitis C was more prevalent than hepatitis B in patients with CLD, viral reactivation was found 3 times more frequently in patients with hepatitis B than C.
- Open Access
- 1 November 2016
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 16 (S4) , 31-76
The 12th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof. Dr. Matei Bals” and the 12th National Infectious Diseases Conference
- 1 November 2016
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 16 (S4) , 31-76
Open AccessThe 12th Edition of the Scientific Days of the National Institute for Infectious Diseases “Prof. Dr. Matei Bals” and the 12th National Infectious Diseases Conference
- Open Access
- 15 October 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S7) , P55
Predictive factors of response to interferon in chronic HBV hepatitis
- 15 October 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S7) , P55
Open AccessPredictive factors of response to interferon in chronic HBV hepatitis
- Open Access
- 15 October 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S7) , P16
The cost-effectiveness of treatment in chronic HBV non-cirrhotic hepatitis – finite versus long-life therapy
- 15 October 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S7) , P16
Open AccessThe cost-effectiveness of treatment in chronic HBV non-cirrhotic hepatitis – finite versus long-life therapy
- Open Access
- 15 October 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S7) , O10
Treatment of chronic HBV hepatitis – between immune control and virological control
- 15 October 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (S7) , O10
Open AccessTreatment of chronic HBV hepatitis – between immune control and virological control
- Open Access
- 16 December 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (S1) , P26
HIV infected pregnant women monitored in the Adults 3 Department of the National Institute for Infectious Diseases “Prof. Dr. Matei Balş” – risk of mother to child transmission
- 16 December 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (S1) , P26
Open AccessHIV infected pregnant women monitored in the Adults 3 Department of the National Institute for Infectious Diseases “Prof. Dr. Matei Balş” – risk of mother to child transmission
- Open Access
- 16 December 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (S1) , O25
Tuberculosis reactivation during novel, biologic therapy
- 16 December 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (S1) , O25
Open AccessTuberculosis reactivation during novel, biologic therapy
- Open Access
- 16 December 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (S1) , O14
In the era of broad spectrum antibiotics, is ampicillin still an option?
- 16 December 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (S1) , O14
Open AccessIn the era of broad spectrum antibiotics, is ampicillin still an option?
- 1 March 2013
- Vol. 22 (1) , 101-4
Type 1 diabetes mellitus with dual autoimmune mechanism related to pegylated interferon and ribavirin treatment for chronic HCV hepatitis.
We report a case of type 1 diabetes mellitus during pegylated interferon and ribavirin treatment for chronic hepatitis C, in a young man previously diagnosed with Hashimoto's thyroiditis and vitiligo. The diabetes mellitus occurred during the 12th month of therapy and the cessation of interferon was necessary. Besides anti-islet autoantibodies our patient had also anti-insulin receptor autoantibodies, which explains the type B insulin resistance. One year after interferon discontinuation the patient continues insulin treatment and all the pancreatic autoantibodies are still positive. Patients with autoimmune disorders should be closely monitored and periodically tested for pancreatic autoantibodies during interferon treatment, even in the absence of hyperglycemia.
- 1 March 2013
- Vol. 22 (1) , 101-4
Type 1 diabetes mellitus with dual autoimmune mechanism related to pegylated interferon and ribavirin treatment for chronic HCV hepatitis.
We report a case of type 1 diabetes mellitus during pegylated interferon and ribavirin treatment for chronic hepatitis C, in a young man previously diagnosed with Hashimoto's thyroiditis and vitiligo. The diabetes mellitus occurred during the 12th month of therapy and the cessation of interferon was necessary. Besides anti-islet autoantibodies our patient had also anti-insulin receptor autoantibodies, which explains the type B insulin resistance. One year after interferon discontinuation the patient continues insulin treatment and all the pancreatic autoantibodies are still positive. Patients with autoimmune disorders should be closely monitored and periodically tested for pancreatic autoantibodies during interferon treatment, even in the absence of hyperglycemia.
- 19 January 2013
- Vol. 50 (2) , 117-27
Trends in hepatitis C virus infection therapy: protease inhibitors a step forward in the era of direct acting antivirals.
The standard of care for the treatment of HCV infected patients was until 2011 the association peginterferon-ribavirin with a sustained virologic response of 50%. In 2011 another class of antivirals was approved by the FDA and EMEA--the HCV-NS3 protease inhibitors. Two molecules are now available: boceprevir and telaprevir. The protease inhibitors are used in association with peginterferon and ribavirin, which remain vital therapy components. Protease inhibitor regimens substantially increased the SVR rate in naive patients and also in previously relapse patients. Because of the high risk of emerging resistance to protease inhibitors, prior null responders are not yet suitable candidates for triple therapy, the SVR rate in these patients is still very low.
- 19 January 2013
- Vol. 50 (2) , 117-27
Trends in hepatitis C virus infection therapy: protease inhibitors a step forward in the era of direct acting antivirals.
The standard of care for the treatment of HCV infected patients was until 2011 the association peginterferon-ribavirin with a sustained virologic response of 50%. In 2011 another class of antivirals was approved by the FDA and EMEA--the HCV-NS3 protease inhibitors. Two molecules are now available: boceprevir and telaprevir. The protease inhibitors are used in association with peginterferon and ribavirin, which remain vital therapy components. Protease inhibitor regimens substantially increased the SVR rate in naive patients and also in previously relapse patients. Because of the high risk of emerging resistance to protease inhibitors, prior null responders are not yet suitable candidates for triple therapy, the SVR rate in these patients is still very low.